Last 7 days
-3.6%
Last 30 days
-22.3%
Last 90 days
-30.2%
Trailing 12 Months
-65.9%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 127.1B | 26.3B | 0.79% | 2.78% | 19.4 | 4.83 | 1.32% | 11.18% |
GILD | 99.8B | 27.3B | -4.19% | 39.66% | 21.72 | 3.66 | -0.09% | -26.23% |
MRNA | 58.1B | 19.3B | -4.61% | -16.03% | 6.95 | 3.02 | 4.29% | -31.47% |
BIIB | 39.0B | 10.2B | -0.92% | 26.77% | 12.8 | 3.83 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.4B | 1.5B | -5.59% | 3.19% | 60.62 | 6.29 | 31.34% | 72.43% |
DNLI | 3.1B | 108.5M | -21.66% | -32.82% | -9.55 | 28.71 | 122.90% | -12.19% |
BBIO | 2.2B | 107.9M | 21.83% | 38.60% | -4.63 | 20.79 | 54.84% | 17.36% |
BEAM | 2.2B | 60.9M | -25.55% | -48.21% | -7.49 | 35.56 | 17.51% | 22.00% |
SMALL-CAP | ||||||||
RCUS | 1.3B | 112.0M | -7.70% | -49.25% | -4.81 | 11.47 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -17.00% | 22.02% | -7.14 | 159.78 | 131.81% | -45.39% |
FATE | 524.4M | 96.3M | -14.58% | -86.07% | -1.86 | 5.45 | 72.44% | -32.79% |
NVAX | 519.7M | 2.0B | -33.63% | -92.58% | -0.79 | 0.26 | 72.89% | 62.27% |
SGMO | 276.9M | 111.3M | -42.96% | -71.96% | -1.44 | 2.49 | 0.54% | -7.86% |
VXRT | 101.6M | 107.0K | -17.23% | -85.52% | -0.94 | 949.93 | -88.00% | -52.91% |
IBIO | 26.0M | - | 40.00% | -84.44% | -0.32 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 6.0% | 215,789,000 | 203,565,000 | 184,209,000 | 163,114,000 | 146,191,000 |
S&GA Expenses | -4.1% | 204,174,000 | 212,949,000 | 197,032,000 | 177,817,000 | 158,208,000 |
R&D Expenses | 7.2% | 128,919,000 | 120,307,000 | 110,144,000 | 93,142,000 | 77,702,000 |
EBITDA | 7.7% | -195,356,000 | -211,694,000 | -204,221,000 | -187,549,000 | - |
EBITDA Margin | 12.9% | -0.91 | -1.04 | -1.11 | -1.15 | - |
Earnings Before Taxes | 6.2% | -214,054,000 | -228,274,000 | -218,352,000 | -200,100,000 | -177,141,000 |
EBT Margin | 11.5% | -0.99 | -1.12 | -1.19 | -1.23 | - |
Interest Expenses | -30.0% | 56,000 | 80,000 | 138,000 | 208,000 | 274,000 |
Net Income | 1.7% | -214,124,000 | -217,863,000 | -207,990,000 | -187,510,000 | -164,761,000 |
Net Income Margin | 7.3% | -0.99 | -1.07 | -1.13 | -1.15 | - |
Free Cahsflow | -2.9% | -232,700,000 | -226,242,000 | -251,405,000 | -211,540,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -5.3% | 910 | 961 | 980 | 1,022 | 786 |
Current Assets | -9.2% | 542 | 596 | 624 | 664 | 385 |
Cash Equivalents | -16.4% | 317 | 379 | 376 | 408 | 193 |
Inventory | 13.5% | 45.00 | 39.00 | 43.00 | 45.00 | 40.00 |
Net PPE | 3.9% | 145 | 139 | 127 | 92.00 | 65.00 |
Goodwill | 0% | 86.00 | 86.00 | 86.00 | 86.00 | 84.00 |
Liabilities | -4.9% | 164 | 172 | 159 | 158 | 160 |
Current Liabilities | -7.5% | 84.00 | 91.00 | 93.00 | 85.00 | 80.00 |
LT Debt, Current | NaN% | - | - | - | - | - |
Shareholder's Equity | -5.5% | 746 | 789 | 821 | 863 | 626 |
Retained Earnings | -5.0% | -870 | -828 | -777 | -716 | -656 |
Additional Paid-In Capital | -0.2% | 1,617 | 1,620 | 1,599 | 1,581 | 1,282 |
Shares Outstanding | 0.2% | 57.00 | 57.00 | 56.00 | 56.00 | 50.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -6.0% | -131 | -124 | -157 | -151 | -133 |
Share Based Compensation | -25.6% | 59.00 | 80.00 | 70.00 | 59.00 | 48.00 |
Cashflow From Investing | 94.3% | -13.32 | -232 | -211 | -111 | -24.51 |
Cashflow From Financing | 0.2% | 271 | 271 | 271 | 271 | 1.00 |
97.4%
97.0%
63.8%
Y-axis is the maximum loss one would have experienced if Twist Bioscience was unfortunately bought at previous high price.
-15.4%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | sold off | -100 | -250,000 | - | -% |
2023-03-10 | BAILLIE GIFFORD & CO | added | 21.84 | -5,550,360 | 25,847,600 | 0.03% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | sold off | -100 | -10,620,000 | - | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -81.99 | -840,000 | 116,000 | -% |
2023-02-28 | Voya Investment Management LLC | added | 0.71 | -17,552,400 | 37,376,600 | 0.05% |
2023-02-24 | NATIXIS | sold off | -100 | -2,892,000 | - | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -43.51 | -379,000 | 220,000 | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | new | - | 500 | 500 | -% |
2023-02-15 | Point72 Middle East FZE | new | - | 15,929 | 15,929 | -% |
2023-02-15 | Virtu Financial LLC | added | 142 | 151,000 | 388,000 | 0.05% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | capital world investors | 1.2% | 704,000 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.24% | 5,229,345 | SC 13G/A | |
Feb 03, 2023 | state street corp | 7.82% | 4,426,249 | SC 13G | |
Feb 03, 2023 | sumitomo mitsui trust holdings, inc. | 5.18% | 2,934,033 | SC 13G | |
Jan 24, 2023 | blackrock inc. | 9.7% | 5,487,180 | SC 13G/A | |
Jan 13, 2023 | jpmorgan chase & co | 6.7% | 3,829,962 | SC 13G | |
Jun 09, 2022 | ark investment management llc | 11.14% | 6,267,721 | SC 13G/A | |
Mar 10, 2022 | fmr llc | - | 0 | SC 13G | |
Feb 11, 2022 | capital world investors | 8.9% | 4,522,700 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 3.95 -75.59% | 4.74 -70.70% | 7.37 -54.45% | 12.04 -25.59% | 21.39 32.20% |
Current Inflation | 3.89 -75.96% | 4.60 -71.57% | 6.89 -57.42% | 10.91 -32.57% | 18.90 16.81% |
Very High Inflation | 3.82 -76.39% | 4.43 -72.62% | 6.33 -60.88% | 9.58 -40.79% | 16.01 -1.05% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 21, 2023 | 4 | Insider Trading | |
Mar 21, 2023 | 4 | Insider Trading | |
Mar 21, 2023 | 4 | Insider Trading | |
Mar 21, 2023 | 4 | Insider Trading | |
Mar 21, 2023 | 4 | Insider Trading | |
Mar 15, 2023 | 4 | Insider Trading | |
Mar 15, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-17 | Cho Dennis | sold (taxes) | -4,210 | 16.51 | -255 | see remarks |
2023-03-17 | Leproust Emily M. | sold (taxes) | -28,859 | 16.51 | -1,748 | chief executive officer |
2023-03-17 | Banyai William | sold (taxes) | -6,901 | 16.51 | -418 | see remarks |
2023-03-17 | Green Paula | sold (taxes) | -3,962 | 16.51 | -240 | svp of human resources |
2023-03-17 | THORBURN JAMES M | sold (taxes) | -8,981 | 16.51 | -544 | chief financial officer |
2023-03-13 | Cho Dennis | sold (taxes) | -1,733 | 16.83 | -103 | see remarks |
2023-02-17 | Yankton Kevin Bruce | sold (taxes) | -1,351 | 22.52 | -60.00 | chief accounting officer |
2023-02-17 | Finn Patrick John | sold (taxes) | -23,128 | 22.52 | -1,027 | president and coo |
2023-02-17 | Leproust Emily M. | sold (taxes) | -61,727 | 22.52 | -2,741 | chief executive officer |
2023-02-17 | THORBURN JAMES M | sold (taxes) | -23,128 | 22.52 | -1,027 | chief financial officer |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | |
Statement of Comprehensive Income [Abstract] | |||
Revenues | $ 203,565 | $ 132,333 | $ 90,100 |
Operating expenses: | |||
Cost of revenues | 119,330 | 80,620 | 61,406 |
Research and development | 120,307 | 69,072 | 43,006 |
Selling, general and administrative | 212,949 | 135,901 | 103,267 |
Change in fair value of contingent considerations and holdbacks | (14,245) | (534) | 0 |
Litigation settlement | 0 | 0 | 22,500 |
Total operating expenses | 438,341 | 285,059 | 230,179 |
Loss from operations | (234,776) | (152,726) | (140,079) |
Interest income | 3,062 | 435 | 1,499 |
Interest expense | (80) | (367) | (787) |
Gain on deconsolidation of subsidiary | 4,607 | 0 | 0 |
Other income (expense), net | (1,087) | (1,370) | (182) |
Loss before income taxes | (228,274) | (154,028) | (139,549) |
Benefit from (provision for) income taxes | 10,411 | 1,930 | (382) |
Net loss attributable to common stockholders | (217,863) | (152,098) | (139,931) |
Other comprehensive loss: | |||
Change in unrealized gain (loss) on investments | (1,594) | (14) | (34) |
Foreign currency translation adjustment | (795) | 473 | (60) |
Comprehensive loss | $ (220,252) | $ (151,639) | $ (140,025) |
Net loss per share attributable to common stockholders—basic (in dollars per share) | $ (4.04) | $ (3.15) | $ (3.57) |
Net loss per share attributable to common stockholders—diluted (in dollars per share) | $ (4.04) | $ (3.15) | $ (3.57) |
Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares) | 53,885 | 48,251 | 39,190 |
Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares) | 53,885 | 48,251 | 39,190 |
Consolidated Balance Sheets - USD ($) | Sep. 30, 2022 | Sep. 30, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 378,687,000 | $ 465,829,000 |
Short-term investments | 126,281,000 | 12,034,000 |
Accounts receivable, net | 40,294,000 | 28,549,000 |
Inventories | 39,307,000 | 31,800,000 |
Prepaid expenses and other current assets | 11,914,000 | 8,283,000 |
Total current assets | 596,483,000 | 546,495,000 |
Property and equipment, net | 139,441,000 | 44,122,000 |
Operating lease right-of-use assets | 74,948,000 | 61,580,000 |
Goodwill | 85,811,000 | 22,434,000 |
Intangible assets, net | 59,738,000 | 18,262,000 |
Restricted cash, non-current | 1,572,000 | 1,530,000 |
Other non-current assets | 3,385,000 | 7,674,000 |
Total assets | 961,378,000 | 702,097,000 |
Current liabilities: | ||
Accounts payable | 20,092,000 | 14,900,000 |
Accrued expenses | 10,169,000 | 6,437,000 |
Accrued compensation | 27,023,000 | 22,327,000 |
Current portion of operating lease liability | 13,642,000 | 8,213,000 |
Current portion of long-term debt | 0 | 1,552,000 |
Other current liabilities | 19,737,000 | 9,623,000 |
Total current liabilities | 90,663,000 | 63,052,000 |
Operating lease liability, net of current portion | 81,270,000 | 53,156,000 |
Other non-current liabilities | 60,000 | 5,068,000 |
Total liabilities | 171,993,000 | 121,276,000 |
Commitments and contingencies | ||
Stockholders’ equity | ||
Common stock, $0.00001 par value — 100,000 and 100,000 shares authorized at September 30, 2022 and 2021, respectively; 56,523 and 49,499 shares issued and outstanding at September 30, 2022 and 2021, respectively | 0 | 0 |
Additional paid-in capital | 1,619,644,000 | 1,190,828,000 |
Accumulated other comprehensive (loss)/income | (1,843,000) | 546,000 |
Accumulated deficit | (828,416,000) | (610,553,000) |
Total stockholders’ equity | 789,385,000 | 580,821,000 |
Total liabilities and stockholders’ equity | $ 961,378,000 | $ 702,097,000 |